Citation Impact
Citing Papers
Oxidative Stress
2017 Standout
Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004.
2006
Educational outreach visits: effects on professional practice and health care outcomes
2007
Beta-thalassemia
2010
Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major
1993
L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy
2003
High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease
1997
Disease-Associated Mutations That Alter the RNA Structural Ensemble
2010
Granulocyte margination in bone marrow: comparison with margination in the spleen and liver
1995
The group II intron ribonucleoprotein precursor is a large, loosely packed structure
2010 StandoutNobel
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases
2009
Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
2015
The β-Thalassemias
1999 Standout
ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance
2010
Evaluation of iron overload
2004
The minimal preprocessing pipelines for the Human Connectome Project
2013 Standout
Iron Overload Cardiomyopathy
2010
Non-compliance—or how many aunts has Matilda?
1993 Standout
Phenotypic conversion of T lymphoblastic lymphoma to acute biphenotypic leukemia composed of lymphoblasts and myeloblasts. Molecular genetic evidence of the same clonal origin.
1988 StandoutNobel
Absence of the TAP2 Human Recombination Hotspot in Chimpanzees
2004 StandoutNobel
What can we learn from T2* maps of the cortex?
2013
6 β-Thalassaemia
1993
Balancing Acts
2004 Standout
Liver iron depletion and toxicity of the iron chelator Deferiprone (L, CP20) in the guinea pig
1997
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha†
2007
Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling
2000 StandoutNobel
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Commentary: Vitamin C: Antioxidant or Pro-Oxidant In Vivo?
1996
Two to Tango: Regulation of Mammalian Iron Metabolism
2010 Standout
Hemoglobin SE disease—A concise review
2007
A role of PIEZO1 in iron metabolism in mice and humans
2021 StandoutNobel
Role of Oxidative Modifications in Atherosclerosis
2004 Standout
Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry
2000
Iron Chelators for Thalassaemia
1998
Drug Antioxidant Effects
1991
Myocarditis
2011 Standout
Bladder cancer
2016 Standout
Chronic hepatitis B
2007 Standout
Developing and evaluating complex interventions: the new Medical Research Council guidance
2008 Standout
A Risk-Benefit Assessment of Iron-Chelation Therapy
1997
A New Mouse Liver-specific Gene, Encoding a Protein Homologous to Human Antimicrobial Peptide Hepcidin, Is Overexpressed during Iron Overload
2001 Standout
Chronic hepatitis B: Update 2009 #
2009 Standout
Insights into RNA structure and function from genome-wide studies
2014 StandoutNobel
Implementation of Evidence-Based Preventive Services Delivery Processes in Primary Care: An Oklahoma Physicians Resource/Research Network (OKPRN) Study
2008
American Gastroenterological Association Technical Review on the Management of Hepatitis C
2006
Adult T-cell leukemia associated with HTLV-I and simultaneous infection by human immunodeficiency virus type 2 and human herpesvirus 6 in an African woman: A clinical, virologic, and familial serologic study
1988 StandoutNobel
Stroke in Children With Sickle Cell Anaemia
2001
Sickle-cell disease
2010 Standout
Recognition of cationic species with synthetic receptors
1997
Raising the profile of genetics in primary care
2004
Protection against tissue damage in vivo by desferrioxamine: What is its mechanism of action?
1989
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Treatment of hepatitis C
2005
Epidemiology of haemoglobin disorders in Europe: an overview
2007
Oxidative mechanisms in the toxicity of metal ions
1995 Standout
Promotion of airway anastomotic microvascular regeneration and alleviation of airway ischemia by deferoxamine nanoparticles
2013 StandoutNobel
Interactions with Aromatic Rings in Chemical and Biological Recognition
2003 Standout
Pulmonary hypertension in patients with thalassemia major
1997
Global epidemiology of haemoglobin disorders and derived service indicators
2008 Standout
Molecular bases of cellular iron toxicity12 1Guest Editor: Mario Comporti 2This article is part of a series of reviews on “Iron and Cellular Redox Status.” The full list of papers may be found on the homepage of the journal.
2002
Recommendations for introducing genetics services in developing countries
2002
5 Thalassaemia: clinical management
1998
Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major
1995
Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major
1998
Disorders of Iron Metabolism
1999 Standout
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species
1993 StandoutScience
Moyamoya Disease and Moyamoya Syndrome
2009 Standout
Continuous low-dose subcutaneous desferrioxamine (DFO) to prevent allergic manifestations in patients with iron overload
1996
MIC2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities
1997
The way forward in HCV treatment — finding the right path
2007 StandoutNobel
Neutrophil recruitment and function in health and inflammation
2013 Standout
Haemoglobinopathies in Europe: health & migration policy perspectives
2014
Protection by Desferrioxamine Against Histopathological Changes of the Liver in the Post-Oligaemic Phase of Clinical Haemorrhagic Shock in Dogs: Correlation with Improved Survival Rate and Recovery
1989
Survival in Medically Treated Patients with Homozygous β-Thalassemia
1994
Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: Comparison of their mechanism of protection with that of desferrioxamine
1992
Iron-Chelating Therapy
1988
Metal ions and oxygen radical reactions in human inflammatory joint disease
1985
Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial
2015
Audit and feedback: effects on professional practice and healthcare outcomes
2012 Standout
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Thiosemicarbazones from the Old to New: Iron Chelators That Are More Than Just Ribonucleotide Reductase Inhibitors
2009
Clinical iron deficiency disturbs normal human responses to hypoxia
2016 StandoutNobel
Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences
2006
The importance of free radicals and catalytic metal ions in human diseases
1985
The C-type lectin SIGN-R1 mediates uptake of the capsular polysaccharide ofStreptococcus pneumoniaein the marginal zone of mouse spleen
2003 StandoutNobel
Limitations of Magnetic Resonance Imaging in Measurement of Hepatic Iron
1997
ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance
2010
Recombination Breakpoints in the Human β-Globin Gene Cluster
1998
RNA modifications by oxidation: A novel disease mechanism?
2012
[1] Role of free radicals and catalytic metal ions in human disease: An overview
1990 Standout
Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo
1995
A Review on Iron Chelators in Treatment of Iron Overload Syndromes.
2016
Phenotypic analysis of acute lymphoblastic leukemia (ALL) cells which are classified as non-T non-B and negative for common ALL antigen
1985
Beta‐thalassaemia intermedia: is it possible consistently to predict phenotype from genotype?
1998
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
1997 Standout
Understudied populations with hepatitis C
2002
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
1988 Standout
A randomised controlled trial of the effect of educational outreach by community pharmacists on prescribing in UK general practice.
2002
Fluorescent Sensors for Measuring Metal Ions in Living Systems
2014 Standout
Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients
1989
Synergistic interaction between differentiation inducers and DNA synthesis inhibitors: A new approach to differentiation induction in myelodysplasia and acute myeloid leukaemia
1985
How I treat transfusional iron overload
2012
Phenotypic conversion of acute leukaemia from T‐lymphoblastic to myeloblastic induced by therapy with 2′‐deoxycoformycin
1983
Oxygen Radicals and Human Disease
1987 Standout
Role of deferiprone in chelation therapy for transfusional iron overload
2003
The Effects of Plant Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and Cancer
2000 Standout
Ferroptosis as a target for protection against cardiomyopathy
2019 Standout
Compliance assessed by the Medication Event Monitoring System.
1991
MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients
2005
Desferrioxamine-chelatable iron, a component of serum non–transferrin-bound iron, used for assessing chelation therapy
2001
Advances in Copper Complexes as Anticancer Agents
2013 Standout
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
Iron-Chelating Therapy and the Treatment of Thalassemia
1997
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Iron overload in thalassemia: different organs at different rates
2017
Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease
2003
Metals in Neurobiology: Probing Their Chemistry and Biology with Molecular Imaging
2008 Standout
Effectiveness of Pentostatin (2‘‐Deoxycoformycin) in Refractory Lymphoid Neoplasms
1984
Surgery of the Spleen
1983
Works of B. Wonke being referenced
Interscanner reproducibility of cardiovascular magnetic resonance T2* measurements of tissue iron in thalassemia
2003
Fertility in β thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature
1995
Hepatic iron concentration combined with long‐term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major
2000
A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload
1996
Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long‐term blood transfusions
2007
Microcytosis, iron deficiency and thalassaemia in a multi‐ethnic community: a pilot study
2007
Effect of different treatment regimes on linear growth and final height in β‐thalassaemia major
1994
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance
2004
High Incidence of Cardiomyopathy in Beta-Thalassaemia Patients Receiving Regular Transfusion and Iron Chelation: Reversal by Intensified Chelation
1990
Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with β‐thalassaemia
1997
A multidisciplinary approach for improving services in primary care: randomised controlled trial of screening for haemoglobin disorders
1998
Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major
1993
Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron
2007
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia
2002
Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients
1997
Development of Thalassaemic Iron Overload Cardiomyopathy despite Low Liver Iron Levels and Meticulous Compliance to Desferrioxamine
2006
A novel δº mutation in cis with Hb Knossos: a study of different genetic interactions in three Egyptian families
1991
Lifetime treatment costs of β-thalassaemia major
1999
Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload
1995
Serum non‐transferrin‐bound iron in beta‐thalassaemia major patients treated with desferrioxamine and L1
1992
Deferiprone‐associated myelotoxicity
1994
Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
1994
The interpretation of platelet kinetic studies for the identification of sites of abnormal platelet destruction
1984
Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators
1995
Assessment of hepatic iron overload in thalassemic patients by magnetic resonance spectroscopy
1994
Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
1987
Iron chelation therapy
1997
Interaction of hemoglobin E and pyrimidine 5' nucleotidase deficiency
1996
USE OF BONE-MARROW CULTURE IN PREDICTION OF ACUTE LEUKAEMIC TRANSFORMATION IN PRELEUKAEMIA
1983
Idiopathic Thrombocytopenic Purpura: A Case of Particular Historic Interest
1980
Efficacy and possible adverse effects of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major [see comments]
1992
5 Results of long-term subcutaneous desferrioxamine therapy
1989
Ocular changes in patients undergoing long-term desferrioxamine treatment.
1984
REMISSION INDUCTION WITH ADENOSINE-DEAMINASE INHIBITOR 2'-DEOXYCOFORMYCIN IN THY-LYMPHOBLASTIC LEUKÆMIA
1980
Moderate reduction of beta-globin gene transcript by a novel mutation in the 5' untranslated region: a study of its interaction with other genotypes in two families
1996
Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
1987
The development of diabetes mellitus and chronic liver disease in long term chelated beta thalassaemic patients
1986
The interpretation of platelet kinetic studies for the identification of sites of abnormal platelet destruction
1984
Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major.
1990
Terminal Deoxynucleotidyl Transferase Expression in Acute Non‐lymphoid Leukaemia: an Analysis by Immunofluorescence
1981
A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload
2003
Combined oral and parenteral iron chelation in beta thalassaemia major.
2000
Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded Patients
1998
A prospective trial of young red cells in 48 patients with transfusion‐dependent thalassaemia
1985